- Home
- ACIU vs TMQ Comparison
ACIU vs TMQ Comparison
Compare ACIU & TMQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- TMQ
- Stock Information
- Founded
- ACIU 2003
- TMQ 2004
- Country
- ACIU Switzerland
- TMQ Canada
- Employees
- ACIU N/A
- TMQ N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- TMQ Precious Metals
- Sector
- ACIU Health Care
- TMQ Basic Materials
- Exchange
- ACIU Nasdaq
- TMQ Nasdaq
- Market Cap
- ACIU 213.3M
- TMQ 249.6M
- IPO Year
- ACIU 2016
- TMQ N/A
- Fundamental
- Price
- ACIU $2.90
- TMQ $6.47
- Analyst Decision
- ACIU Strong Buy
- TMQ
- Analyst Count
- ACIU 2
- TMQ 0
- Target Price
- ACIU $10.00
- TMQ N/A
- AVG Volume (30 Days)
- ACIU 343.9K
- TMQ 31.7M
- Earning Date
- ACIU 11-04-2025
- TMQ 09-30-2025
- Dividend Yield
- ACIU N/A
- TMQ N/A
- EPS Growth
- ACIU N/A
- TMQ N/A
- EPS
- ACIU N/A
- TMQ N/A
- Revenue
- ACIU $36,362,036.00
- TMQ N/A
- Revenue This Year
- ACIU N/A
- TMQ N/A
- Revenue Next Year
- ACIU $1,022.98
- TMQ N/A
- P/E Ratio
- ACIU N/A
- TMQ N/A
- Revenue Growth
- ACIU 86.71
- TMQ N/A
- 52 Week Low
- ACIU $1.43
- TMQ $0.52
- 52 Week High
- ACIU $3.99
- TMQ $11.29
- Technical
- Relative Strength Index (RSI)
- ACIU 47.76
- TMQ 59.29
- Support Level
- ACIU $2.89
- TMQ $6.00
- Resistance Level
- ACIU $3.21
- TMQ $11.29
- Average True Range (ATR)
- ACIU 0.33
- TMQ 1.13
- MACD
- ACIU -0.08
- TMQ 0.33
- Stochastic Oscillator
- ACIU 3.95
- TMQ 48.98
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the United States. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.